323 related articles for article (PubMed ID: 33146922)
1. A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.
Zheng H; Mineishi S; Claxton D; Zhu J; Zhao C; Jia B; Ehmann WC; Rybka WB; Naik S; Songdej N; Drabick JJ; Hohl RJ
Am J Hematol; 2021 Feb; 96(2):E46-E50. PubMed ID: 33146922
[No Abstract] [Full Text] [Related]
2. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P; Roboz GJ; Bulabois CE; Subklewe M; Platzbecker U; Ofran Y; Papayannidis C; Wierzbowska A; Shin HJ; Doronin V; Deneberg S; Yeh SP; Ozcan MA; Knapper S; Cortes J; Pollyea DA; Ossenkoppele G; Giralt S; Döhner H; Heuser M; Xiu L; Singh I; Huang F; Larsen JS; Wei AH
Leukemia; 2021 Jan; 35(1):62-74. PubMed ID: 32203138
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Fathi AT; Erba HP; Lancet JE; Stein EM; Ravandi F; Faderl S; Walter RB; Advani AS; DeAngelo DJ; Kovacsovics TJ; Jillella A; Bixby D; Levy MY; O'Meara MM; Ho PA; Voellinger J; Stein AS
Blood; 2018 Sep; 132(11):1125-1133. PubMed ID: 30045838
[TBL] [Abstract][Full Text] [Related]
5. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Erba HP
Leuk Res; 2015 Feb; 39(2):183-91. PubMed ID: 25577399
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Ravandi F; Estey E; Wang X; Garcia-Manero G; Jabbour E; Konopleva M; O'Brien S; Verstovsek S; Kadia T; Dinardo C; Pierce S; Huang X; Pemmaraju N; Diaz-Pines-Mateo M; Cortes J; Borthakur G
Leukemia; 2016 Feb; 30(2):268-73. PubMed ID: 26365212
[TBL] [Abstract][Full Text] [Related]
7. Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
Zhang X; Guo X
Ann Hematol; 2019 Sep; 98(9):2223-2225. PubMed ID: 30980106
[No Abstract] [Full Text] [Related]
8. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
10. Venetoclax with decitabine or azacitidine for AML.
Das M
Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
[No Abstract] [Full Text] [Related]
11. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.
Sun W; Triche T; Malvar J; Gaynon P; Sposto R; Yang X; Bittencourt H; Place AE; Messinger Y; Fraser C; Dalla-Pozza L; Salhia B; Jones P; Wayne AS; Gore L; Cooper TM; Liang G
Blood; 2018 Mar; 131(10):1145-1148. PubMed ID: 29339403
[No Abstract] [Full Text] [Related]
12. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
Cortes J; Podoltsev N; Kantarjian H; Borthakur G; Zeidan AM; Stahl M; Taube T; Fagan N; Rajeswari S; Uy GL
Int J Hematol; 2021 Jan; 113(1):92-99. PubMed ID: 32951163
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
Abaza Y; Kantarjian H; Alwash Y; Borthakur G; Champlin R; Kadia T; Garcia-Manero G; Daver N; Ravandi F; Verstovsek S; Burger J; Estrov Z; Ohanian M; Lim M; Pemmaraju N; Jabbour E; Cortes J
Am J Hematol; 2020 Nov; 95(11):1288-1295. PubMed ID: 32681739
[TBL] [Abstract][Full Text] [Related]
14. Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.
Kearns P; Zwaan CM; Reinhardt D; Gibson B; Moreno L; Nysom K; Nakahara S; Huang F; Zhou W; Parasrampuria DA; Nemat S
Br J Haematol; 2019 Aug; 186(3):e7-e11. PubMed ID: 30847896
[No Abstract] [Full Text] [Related]
15. Decitabine Compared With Conventional Regimens in Older Patients With Acute Myeloid Leukemia: A Meta-Analysis.
Bian MR; Yang HS; Lin GQ; Wan Y; Wang L; Si YJ; Zhang XX; Wang M; Zhou H; Zhao GS; Zhang YM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):e636-e648. PubMed ID: 31645307
[TBL] [Abstract][Full Text] [Related]
16. [Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy].
Tauveron-Jalenques U; Lambert J
Bull Cancer; 2024 May; 111(5):435-436. PubMed ID: 38582741
[No Abstract] [Full Text] [Related]
17. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
[No Abstract] [Full Text] [Related]
18. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
